Clinical trials sponsored by iRegene Therapeutics Co., Ltd.

Phase breakdown

Conditions studied

Recruiting trials led by iRegene Therapeutics Co., Ltd.

• The Safety, Tolerability and Efficacy of NouvNeu001 for Parkinson's Disease
  NCT06167681 · Phase: Phase 1, Phase 2 · Ages: 50 Years to 75 Years · Sex: All (male and female) · 2 locations
• The Safety, Tolerability and Preliminary Efficacy of NouvNeu001 for Early-onset Parkinson's Disease
  NCT06608355 · Phase: Phase 1 · Ages: 18 Years to 70 Years · Sex: All (male and female) · 1 location
• This Clinical Trial is Designed to Evaluate the Safety, Tolerability, Feasibility and Preliminary Efficacy of NouvNeu001 (Human Dopaminergic Progenitor Cells Injection) in Patients With Parkinson's Disease.
  NCT07102342 · Phase: Phase 1, Phase 2 · Ages: 30 Years to 75 Years · Sex: All (male and female) · 1 location

Common questions

How many trials is iRegene Therapeutics Co., Ltd. recruiting for?

iRegene Therapeutics Co., Ltd. is the lead sponsor of 3 recruiting trials.

Is this list complete?

No. For the full record, search ClinicalTrials.gov.